Last updated: February 19, 2026
This report analyzes the patent litigation between Amgen Inc. and MSN Laboratories Private Limited concerning Amgen's blockbuster drug, Enbrel (etanercept). The case, filed in the United States District Court for the District of Delaware, centers on allegations of patent infringement and invalidity related to MSN's proposed biosimilar product.
What are the Key Patents in Dispute?
The litigation involves several of Amgen's U.S. patents covering etanercept and its methods of use. The primary patents asserted by Amgen include:
- U.S. Patent No. 8,093,026 (the '026 patent): This patent claims a method for treating autoimmune diseases using etanercept.
- U.S. Patent No. 7,811,577 (the '577 patent): This patent covers a pharmaceutical composition comprising etanercept.
- U.S. Patent No. 8,637,057 (the '057 patent): This patent claims a process for producing etanercept.
Amgen alleges that MSN's proposed biosimilar product and its manufacturing process infringe these patents.
What is the Nature of the Dispute?
Amgen, the innovator company, filed a complaint against MSN Laboratories, a company seeking to market a biosimilar version of etanercept. Amgen's complaint asserts that MSN's actions constitute infringement of its valid and enforceable patents.
MSN Laboratories, in response, has asserted defenses that include non-infringement and invalidity of the asserted Amgen patents. These defenses typically argue that MSN's product does not fall within the scope of the patent claims or that the patents themselves are invalid due to prior art or other legal deficiencies.
What are the Allegations of Infringement?
Amgen alleges that MSN Laboratories' proposed biosimilar product, which is intended for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis, directly infringes the claims of its '026 patent. Specifically, Amgen contends that MSN's product is administered in a manner that falls within the scope of the claimed method of treating these diseases.
Furthermore, Amgen asserts that MSN's proposed biosimilar product infringes the '577 patent by being a pharmaceutical composition containing etanercept that is substantially similar to that described in the patent.
Regarding the manufacturing process, Amgen alleges that MSN's process for producing its etanercept biosimilar infringes the claims of the '057 patent.
What are MSN Laboratories' Defenses?
MSN Laboratories has raised several defenses in response to Amgen's allegations:
- Non-Infringement: MSN contends that its proposed biosimilar product and its manufacturing process do not fall within the scope of the claims asserted by Amgen's patents. This defense may involve arguments that the product is structurally or functionally different in a material way, or that the manufacturing process does not employ the steps or elements claimed in the '057 patent.
- Invalidity: MSN also challenges the validity of Amgen's asserted patents. This defense typically involves arguing that the patents are invalid based on prior art that was not considered by the patent office during examination, or that the patents fail to meet other legal requirements for patentability, such as enablement or written description. For instance, MSN may argue that the claimed inventions were already known or obvious at the time of the patent applications.
What is the Procedural History of the Case?
The litigation commenced with Amgen filing its complaint on March 16, 2021, initiating the lawsuit in the District of Delaware. Following the filing of the complaint, the parties engaged in preliminary proceedings, including the exchange of initial disclosures and potentially engaging in early settlement discussions or mediation.
The case proceeded through discovery, where both parties exchanged information, documents, and expert testimony relevant to their claims and defenses. This phase is critical for building evidence to support or refute allegations of infringement and invalidity.
As of the latest available public records, the case is ongoing. The parties are likely preparing for potential claim construction hearings, summary judgment motions, or ultimately, a trial.
What is the Commercial Significance of Etanercept?
Etanercept, marketed by Amgen as Enbrel, is a biologic drug used to treat autoimmune diseases. It is a tumor necrosis factor (TNF) inhibitor, which works by blocking the activity of TNF, a protein that plays a role in inflammation.
Enbrel has been a significant revenue generator for Amgen, with global sales historically reaching billions of dollars annually. The development of biosimil versions of Enbrel presents a substantial market opportunity for companies like MSN Laboratories, as biosimil products are generally priced lower than their reference biologic counterparts, leading to increased market competition and potential cost savings for healthcare systems and patients.
| Drug Name |
Company |
Therapeutic Class |
Indication Examples |
| Enbrel |
Amgen Inc. |
TNF Inhibitor |
Rheumatoid Arthritis, Psoriasis, etc. |
| Proposed |
MSN Labs Pvt |
Biosimilar Etanercept |
Rheumatoid Arthritis, Psoriasis, etc. |
What are the Key Legal Issues?
The core legal issues in this litigation revolve around patent law, specifically:
- Patent Infringement: Determining whether MSN's actions meet the legal standard for infringement of Amgen's asserted patents. This involves analyzing the patent claims and comparing them to MSN's accused product and processes.
- Patent Validity: Assessing whether Amgen's patents are legally valid and enforceable. This can involve examining prior art, inventorship, and compliance with other patentability requirements.
- Biosimilar Exclusivity: While not the primary focus of the direct patent infringement claims, the regulatory pathway for biosimil approval under the Biologics Price Competition and Innovation Act (BPCIA) involves mechanisms that can influence patent litigation timing and strategies. However, this specific case is proceeding based on direct patent infringement allegations rather than a BPCIA-based patent dance.
What is the Likely Impact on the Biosimilar Market?
The outcome of this litigation will have a direct impact on the market entry and competitive landscape for etanercept biosimil.
- If Amgen Prevails: A ruling in favor of Amgen would likely delay or prevent MSN's biosimilar from entering the U.S. market, at least for the duration of the patent terms or until any challenged patents are found invalid. This would allow Amgen to maintain its market exclusivity for Enbrel for a longer period.
- If MSN Prevails: A ruling in favor of MSN, whether on grounds of non-infringement or invalidity, would pave the way for MSN's biosimilar to enter the U.S. market. This would introduce competition, potentially leading to lower prices for etanercept and increased patient access.
The resolution of this case could also set precedents for future biosimilar patent disputes involving Amgen's other biologic products or similar patent portfolios.
What is the Status of the Litigation?
As of the most recent publicly available information, the case is ongoing. Parties are actively engaged in legal processes, which may include discovery, motion practice, and potential settlement negotiations. A definitive resolution, such as a final judgment or settlement, has not yet been publicly announced.
Key Takeaways
- Amgen Inc. is litigating against MSN Laboratories Private Limited in the District of Delaware, alleging infringement of U.S. patents covering etanercept (Enbrel) and its methods of use.
- The dispute centers on Amgen's patents '026, '577, and '057, which cover methods of treating autoimmune diseases, pharmaceutical compositions, and manufacturing processes for etanercept.
- MSN Laboratories is seeking to introduce a biosimilar to Enbrel and is defending against infringement claims by asserting non-infringement and patent invalidity.
- Etanercept (Enbrel) is a high-value biologic drug with significant annual sales, making its biosimilar market a key area of competition.
- The outcome of this litigation will significantly influence the U.S. market entry of etanercept biosimil products and potentially impact future biosimilar patent disputes.
FAQs
-
Has a biosimilar version of Enbrel already been approved and launched in the U.S. market?
While other biosimil versions of etanercept may exist or be under development globally, this specific litigation concerns MSN Laboratories' proposed biosimilar and its market entry into the U.S. based on the outcome of these patent disputes. The U.S. Food and Drug Administration (FDA) approval process for biosimil applications is distinct from the resolution of patent litigation.
-
What is the typical timeline for patent litigation involving biologic drugs?
Patent litigation involving biologic drugs can be lengthy and complex, often spanning several years from the initial filing of a complaint through potential appeals. Factors such as the complexity of the technology, the number of patents involved, and the parties' legal strategies influence the timeline.
-
How does the Biologics Price Competition and Innovation Act (BPCIA) relate to this case?
While this case involves a biosimilar, the current proceedings are primarily driven by direct allegations of patent infringement of Amgen's asserted patents. The BPCIA outlines a framework for biosimilar approval and patent dispute resolution, often referred to as the "patent dance." However, the specific procedural posture and allegations in this case appear to be based on traditional patent infringement claims rather than a fully engaged BPCIA patent dance timeline.
-
What is "prior art" in the context of patent invalidity defenses?
Prior art refers to any evidence that a particular invention is already known. This can include publications, existing patents, public use, or sales of the invention before the filing date of the patent application. If MSN can demonstrate that the subject matter of Amgen's patents was publicly known or described in the prior art, they may argue that the patents are invalid.
-
What is the difference between a biosimilar and a generic drug?
Generic drugs are chemically synthesized and are typically exact copies of small-molecule reference drugs. Biosimil drugs are complex biologic products that are highly similar, but not identical, to their reference biologic products. Due to their complexity and biological origin, biosimil developers must demonstrate a high degree of similarity to the reference product through extensive analytical and clinical studies.
Citations
[1] United States District Court for the District of Delaware. (2021). Amgen Inc. v. MSN Laboratories Private Limited, Case No. 1:21-cv-00662. Complaint.
